New Data Demonstrates Sandoz’ Etanercept and Rituximab Biosimilar Candidates Bioequivalent to Originator Products
Holzkirchen, June 9 2016 – Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, today announced results from two key studies…